EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Assessment of Potential Drug-Drug Interactions between Nirmatrelvir/Ritonavir and Concomitant Drugs among Coronavirus Disease Patients in a Tertiary Care Hospital.

Shamala Balan, Kavidha Mohan

Asian Journal of Medicine & Health Sciences · 28.05.2025 · 8 (1)

DOI: 10.70672/0r53dt64 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Medicine & Health Sciences, online erschienen am 28.05.2025. Verfasst von Shamala Balan und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nirmatrelvir/ritonavir is indicated for the treatment of COVID-19infection. However, potential drug-drug interactions (pDDI) between nirmatrelvir/ritonavir and concomitant drugs require further investigation.

Objective

To assess the prevalence, management, and risk factors of pDDI between nirmatrelvir/ritonavir and concomitant drugs in patients with COVID-19 .

Methods

This cross-sectional study was approved by the Medical Research Ethics Committee of Malaysia. Inclusion criteria were COVID-19 patients aged ≥18 years, treated with nirmatrelvir/ritonavir between July and September 2022 in a tertiary care hospital in Selangor. Classification and management of pDDI were categorised according to the University of Liverpool COVID-19 Drug Interactions classification. The pDDI management in clinical practice was compared to the recommended classifications and categorised as 'compliant' or 'non-compliant. Patient characteristics were analysed descriptively. Binary logistic regression was used to identify pDDI risk factors.

Results

The study included 189 patients with a mean age ±SD of 56.76±18.68 years. Comorbidities and polypharmacy were observed in 147 (77.78%) and 73 (38.62%) patients, respectively. A total of 114 patients (60.32%) were reported to have at least one pDDI with nirmatrelvir/ritonavir. Most concomitant drugs had potential interactions with nirmatrelvir/ritonavir (n=152, 77.16%). Compliance with the recommended pDDI management was observed in 174 (88.32%) drug entries. Age (OR 1.04; 1.02-1.06; p=0.001), comorbidities (OR 8.87; 3.17-24.78; p

Zitieren

APA

Balan, S., & Mohan, K. (2025). Assessment of Potential Drug-Drug Interactions between Nirmatrelvir/Ritonavir and Concomitant Drugs among Coronavirus Disease Patients in a Tertiary Care Hospital. Asian Journal of Medicine & Health Sciences, 8(1). https://doi.org/10.70672/0r53dt64

Vancouver

Balan S, Mohan K. Assessment of Potential Drug-Drug Interactions between Nirmatrelvir/Ritonavir and Concomitant Drugs among Coronavirus Disease Patients in a Tertiary Care Hospital. Asian Journal of Medicine & Health Sciences. 2025;8(1). doi:10.70672/0r53dt64

BibTeX
@article{Balan2025,
  author = {Balan, Shamala and Mohan, Kavidha},
  title = {Assessment of Potential Drug-Drug Interactions between Nirmatrelvir/Ritonavir and Concomitant Drugs among Coronavirus Disease Patients in a Tertiary Care Hospital},
  journal = {Asian Journal of Medicine & Health Sciences},
  year = {2025},
  volume = {8},
  number = {1},
  doi = {10.70672/0r53dt64}
}
Kostenlos starten →